NIH Kicks Off Head-To-Head Avastin/Lucentis Study
This article was originally published in The Pink Sheet Daily
Executive Summary
Outcome could hinder Genentech's Lucentis sales, if results show Avastin is more cost-effective.
You may also be interested in...
Regeneron/Bayer Bullish On Wet-AMD Drug But Commercial Success Is No Guarantee
Positive results of two Phase III studies show VEGF Trap-Eye candidate has potential for dosing every two months, but competing against Roche's Lucentis and off-label Avastin won't be easy.
Regeneron/Bayer Bullish On Wet-AMD Drug But Commercial Success Is No Guarantee
Positive results of two Phase III studies show VEGF Trap-Eye candidate has potential for dosing every two months, but competing against Roche's Lucentis and off-label Avastin won't be easy.
End Of The Year Approvals And Actions, In Brief
Ferring plans prostate cancer drug launch: After securing FDA approval of degarelix for advanced prostate cancer, the Swiss pharma is planning a launch in the first quarter after finalizing the trade name with FDA. Degarelix is a gonadotropin releasing hormone receptor antagonist that suppresses testosterone, and could have an advantage over existing hormonal treatments like Abbott's Lupron Depot because it hasn't shown the initial surge in testosterone production that has been seen with some other agents, according to FDA. Testosterone plays an important role in the growth of prostate cancer, so suppressing testosterone can slow the growth and progression of prostate tumors. Degarelix was compared to leuprolide in the Phase III study supporting approval. For the U.S. launch, Ferring plans to expand its existing urology sales force from 85 reps to 115